Exact Sciences Corp. completed its acquisition of cancer-screening firm Thrive Earlier Detection Corp., according to a company release.
The $2.17 billion acquisition of Thrive along with the $410 million purchase of Base Genomics advances Exact Sciences’ efforts to be a leader in blood-based cancer screening. Exact Sciences is known for its at-home colon cancer screening test Cologuard.
